Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $226,590.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the transaction, the insider directly owned 34,018 shares in the company, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Joana Goncalves also recently made the following trade(s):

• On Thursday, January 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $31.81, for a total value of $222,670.00.
• On Friday, December 19th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00.

Oruka Therapeutics Trading Up 1.5%

Shares of Oruka Therapeutics stock traded up $0.47 on Tuesday, reaching $32.68. 260,669 shares of the stock were exchanged, compared to its average volume of 460,718. The firm has a market capitalization of $1.58 billion, a PE ratio of -17.20 and a beta of -0.39. The business has a fifty day moving average price of $31.61 and a two-hundred day moving average price of $25.08. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $36.51.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wedbush raised their price target on Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Piper Sandler assumed coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price on the stock. HC Wainwright decreased their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, October 27th. Finally, BTIG Research lifted their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ORKA. Fairmount Funds Management LLC increased its position in shares of Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares in the last quarter. Viking Global Investors LP acquired a new position in shares of Oruka Therapeutics during the third quarter worth about $51,280,000. Deep Track Capital LP grew its holdings in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares in the last quarter. Vanguard Group Inc. raised its position in Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after buying an additional 676,865 shares during the last quarter. Finally, Commodore Capital LP raised its position in Oruka Therapeutics by 23.5% in the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after buying an additional 333,340 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.